Trial · NCT03143153
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With Tumor Cell PD-L1 | Arm A: Nivolumab + Ipilimumab | 13.70 | 95% Confidence Interval 11.24 to 17.02 | Months | |
| Overall Survival (OS) in Participants With Tumor Cell PD-L1 | Arm B: Nivolumab + Chemotherapy | 15.44 | 95% Confidence Interval 11.93 to 19.52 | Months | |
| Overall Survival (OS) in Participants With Tumor Cell PD-L1 | Arm C: Chemotherapy | 9.07 | 95% Confidence Interval 7.69 to 9.95 | Months | |
| Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1 | Arm A: Nivolumab + Ipilimumab | 4.04 | 95% Confidence Interval 2.40 to 4.93 | Months | |
| Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1 | Arm B: Nivolumab + Chemotherapy | 6.93 | 95% Confidence Interval 5.68 to 8.34 | Months | |
| Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1 | Arm C: Chemotherapy | 4.44 | 95% Confidence Interval 2.89 to 5.82 | Months | |
| Overall Survival (OS) in All Randomized Participants | Arm A: Nivolumab + Ipilimumab | 12.747 | 95% Confidence Interval 11.269 to 15.474 | Months | |
| Overall Survival (OS) in All Randomized Participants | Arm B: Nivolumab + Chemotherapy | 13.207 | 95% Confidence Interval 11.105 to 15.671 | Months | |
| Overall Survival (OS) in All Randomized Participants | Arm C: Chemotherapy | 10.710 | 95% Confidence Interval 9.396 to 12.090 | Months | |
| Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR | Arm A: Nivolumab + Ipilimumab | 2.891 | 95% Confidence Interval 2.661 to 4.172 | Months | |
| Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR | Arm B: Nivolumab + Chemotherapy | 5.782 | 95% Confidence Interval 5.520 to 6.998 | Months | |
| Progression-free Survival (PFS) in All Randomized Participants as Assessed by BICR | Arm C: Chemotherapy | 5.618 | 95% Confidence Interval 4.304 to 5.914 | Months | |
| Objective Response Rate (ORR) as Assessed by BICR | Arm A: Nivolumab + Ipilimumab | Participants with baseline PD-L1 status < 1% | 20.1 | 95% Confidence Interval 14.3 to 27.1 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm B: Nivolumab + Chemotherapy | Participants with baseline PD-L1 status < 1% | 41.7 | 95% Confidence Interval 34.1 to 49.7 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm C: Chemotherapy | Participants with baseline PD-L1 status < 1% | 33.7 | 95% Confidence Interval 26.6 to 41.5 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm A: Nivolumab + Ipilimumab | Participants with baseline PD-L1 status >= 1% | 35.4 | 95% Confidence Interval 28.0 to 43.4 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm B: Nivolumab + Chemotherapy | Participants with baseline PD-L1 status >= 1% | 53.2 | 95% Confidence Interval 45.1 to 61.1 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm C: Chemotherapy | Participants with baseline PD-L1 status >= 1% | 19.9 | 95% Confidence Interval 13.9 to 27.0 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm A: Nivolumab + Ipilimumab | Participants with baseline PD-L1 status < 5% | 22.3 | 95% Confidence Interval 16.7 to 28.6 | Percentage of participants |
| Objective Response Rate (ORR) as Assessed by BICR | Arm B: Nivolumab + Chemotherapy | Participants with baseline PD-L1 status < 5% | 44.8 | 95% Confidence Interval 37.8 to 51.9 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03143153/results